- Business Wire•24 days ago
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016, from 3:45-4:25 p.m.
- Associated Press•26 days ago
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 68 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Business Wire•26 days ago
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today reported financial and operational results for the third quarter ended September 30, 2016.
DRNA : Summary for Dicerna Pharmaceuticals, Inc. - Yahoo Finance
Dicerna Pharmaceuticals, Inc. (DRNA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||2.72 x 200|
|Ask||4.96 x 800|
|Day's Range||2.90 - 3.07|
|52 Week Range||2.69 - 15.93|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.07|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|